According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).
New research is signaling that a simple and cost-effective biomarker may be used to monitor the severity of hidradenitis suppurativa (HS).
The retrospective study of patients with the condition showed that pan-immune-inflammation value (PIV), across a variety of biomarkers, had the strongest indications for HS severity. According to the researchers, whose findings appear in Journal of the European Academy of Dermatology and Venereology, the biomarker may be able to be used with clinical scores in treatment decisions or in clinical trials.
“In routine clinic evaluation of HS disease, severity based only on clinical features can be a challenge (eg, distinguishing Hurley II and Hurley III),” explained the researchers. “Hence, diagnostic and monitoring biomarkers for HS are needed. Data regarding the association of serum markers of inflammation with HS disease severity have recently been reported by our research group.”
Across the 142 patients with HS and 35 sex- and age-matched controls, the researchers saw a significant positive correlation between modified HS score (mHSS) and PIV (r = 0.32; P < .0001), in addition to neutrophil to lymphocyte ratio (NLR) (r = 0.17; P = .0415), monocyte to lymphocyte ratio (MLR) (r = 0.23; P = .0052), and systemic immune-inflammation index (SII) (r = 0.19; P = 0.0222). They also found that the platelet to neutrophil ratio (PNR) had a negative correlation with mHSS (r = –0.21; P = .0124).
Compared with the controls, patients with HS had significantly higher PIV and SII, although PIV—a combination of neutrophil, platelet, and monocyte counts—was the only biomarker significantly associated with severity based on the Youden index, with an index of 0.56.
PIV also showed an area under the curve (AUC) of 0.79 (95% CI, 0.71-0.85; P < .0001), with a sensitivity of 59.3 and a specificity of 96.5.
The platelet to lymphocyte ratio (PLR), MLR, and PNR were all significantly lower in these patients compared with the controls. Previous research has connected NLR and PLR with the severity of skin inflammatory diseases, although this correlation has not previously been studied in HS specifically.
“On the basis of our data, PLR does not appear to be a suitable biomarker for disease activity or severity,” described the researchers. “By contrast, NLR, MLR, PNR, SII, and PIV positively or negatively correlated with HS severity. However, the AUC values for Hurley stage and [Severity Assessment of Hidradenitis Suppurativa score] were relatively poor for NLR, MLR, PNR, and SII.”
Reference
Gambichler T, Hessam S, Cramer P, Rached NA, Bechara G. Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. Published online April 24, 2022. doi:10.1111/jdv.18175
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More